Overexpression of urokinase by plaque macrophages causes histological features of plaque rupture and increases vascular matrix metalloproteinase activity in aged apolipoprotein E-Null mice

Circulation

Volumn 121, Issue 14, 2010, Pages 1637-1644

  Hu, Jie Hong ^a   Du, Liang ^a   Chu, Talyn ^a   Otsuka, Goro ^a   Dronadula, Nagadhara ^a   Jaffe, Mia ^a   Gill, Sean E ^a   Parks, William C ^a   Dichek, David A ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Atherosclerosis; Hemorrhage; Metalloproteinases; Plaque; Urokinase

Indexed keywords

APOLIPOPROTEIN E; ELASTIN; FIBRIN; GELATINASE B; MATRIX METALLOPROTEINASE; UROKINASE;

AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA ROOT; AORTA RUPTURE; ARTICLE; ATHEROSCLEROTIC PLAQUE; BLEEDING; BODY WEIGHT; BONE MARROW; BRACHIOCEPHALIC TRUNK; CELL TRANSPLANTATION; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; ENZYME ACTIVITY; GENE OVEREXPRESSION; HEMATOPOIETIC CELL; HISTOPATHOLOGY; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL;

ANIMALS; ANTIGENS, DIFFERENTIATION; APOLIPOPROTEINS E; BONE MARROW; BONE MARROW TRANSPLANTATION; BRACHIOCEPHALIC TRUNK; CARDIOVASCULAR DISEASES; GENE EXPRESSION REGULATION; GENES, REPORTER; HEMATOPOIESIS; HUMANS; MALE; MATRIX METALLOPROTEINASES; MICE; MICE, KNOCKOUT; PLASMINOGEN; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 77950920338     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.109.914945     Document Type: Article

References (48)

1. Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation. 1995; 92:657-671.
2. Hennerici MG. The unstable plaque. Cerebrovasc Dis. 2004; 17(suppl 3):17-22.
3. Mann J, Davies MJ. Mechanisms of progression in native coronary artery disease: role of healed plaque disruption. Heart. 1999;82:265-268.
4. Libby P. The molecular mechanisms of the thrombotic complications of atherosclerosis. J Intern Med. 2008;263:517-527.
5. Clarke M, Bennett M. The emerging role of vascular smooth muscle cell apoptosis in atherosclerosis and plaque stability. Am J Nephrol. 2006;26: 531-535. (Pubitemid 46143874)
6. Lindstedt KA, Leskinen MJ, Kovanen PT. Proteolysis of the pericellular matrix: a novel element determining cell survival and death in the pathogenesis of plaque erosion and rupture. Arterioscler Thromb Vasc Biol. 2004;24:1350-1358.
7. Myoishi M, Hao H, Minamino T, Watanabe K, Nishihira K, Hatakeyama K, Asada Y, Okada K, Ishibashi-Ueda H, Gabbiani G, Bochaton-Piallat ML, Mochizuki N, Kitakaze M. Increased endoplasmic reticulum stress in atherosclerotic plaques associated with acute coronary syndrome. Circulation. 2007;116:1226-1233.
8. Dunmore BJ, McCarthy MJ, Naylor AR, Brindle NP. Carotid plaque instability and ischemic symptoms are linked to immaturity of microvessels within plaques. J Vasc Surg. 2007;45:155-159.
9. Folts J. Arterial blood pressure gradient across vulnerable plaque might increase rupture. J Am Coll Cardiol. 2007;50:2440.
10. Thim T, Hagensen MK, Bentzon JF, Falk E. From vulnerable plaque to atherothrombosis. J Intern Med. 2008;263:506-516.
11. Cheng C, Tempel D, van Haperen R, van der Baan A, Grosveld F, Daemen MJ, Krams R, de Crom R. Atherosclerotic lesion size and vulnerability are determined by patterns of fluid shear stress. Circulation. 2006;113:2744-2753.
12. Galis ZS, Sukhova GK, Lark MW, Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest. 1994;94: 2493-2503
13. ShahPK. Molecular mechanisms of plaque instability. Curr Opin Lipidol. 2007;18:492-499.
14. Halpert I, Sires UI, Roby JD, Potter-Perigo S, Wight TN, Shapiro SD, Welgus HG, Wickline SA, Parks WC. Matrilysin is expressed by lipid-laden macrophages at sites of potential rupture in atherosclerotic lesions and localizes to areas of versican deposition, a proteoglycan substrate for the enzyme. Proc Natl Acad Sci USA. 1996;93:9748-9753.
15. Ra HJ, Parks WC. Control of matrix metalloproteinase catalytic activity. Matrix Biol. 2007;26:587-596.
16. Falkenberg M, Giglio D, Bjornheden T, Nygren H, Risberg B. Urokinase plasminogen activator colocalizes with CD25+ cells in atherosclerotic vessels. J Vasc Res. 1998;35:318-324.
17. Lupu F, Heim DA, Bachmann F, Hurni M, Kakkar VV, Kruithof EKO. Plasminogen activator expression in human atherosclerotic lesions. Arterioscler Thromb Vasc Biol. 1995;15:1444-1455.
18. Carmeliet P, Moons L, Lijnen R, Baes M, Lemaitre V, Tipping P, Drew A, Eeckhout Y, Shapiro S, Lupu F, Collen D. Urokinase-generated plasmin activates matrix metalloproteinases during aneurysm formation. Nat Genet. 1997;17:439-444.
19. Lijnen HR. Plasmin and matrix metalloproteinases in vascular remodeling. Thromb Haemost. 2001;86:324-333.
20. Newby AC. Metalloproteinases and vulnerable atherosclerotic plaques. Trends Cardiovasc Med. 2007;17:253-258.
21. de Nooijer R, Verkleij CJ, von der Thusen JH, Jukema JW, van der Wall EE, van Berkel TJ, Baker AH, Biessen EA. Lesional overexpression of matrix metalloproteinase-9 promotes intraplaque hemorrhage in advanced lesions but not at earlier stages of atherogenesis. Arterioscler Thromb Vasc Biol. 2006;26:340-346.
22. Gough PJ, Gomez IG, Wille PT, Raines EW. Macrophage expression of active MMP-9 induces acute plaque disruption in apoE-deficient mice. J Clin Invest. 2006;116:59-69.
23. Cozen AE, Moriwaki H, Kremen M, DeYoung MB, Dichek HL, Slezicki KI, Young SG, Veniant M, Dichek DA. Macrophage-targeted overex-pression of urokinase causes accelerated atherosclerosis, coronary artery occlusions, and premature death. Circulation. 2004;109:2129-2135.
24. Kremen M, Krishnan R, Emery I, Hu JH, Slezicki K, Wu A, Qian K, Du L, Plawman A, Stempien-Otero A, Dichek DA. Plasminogen mediates the atherogenic effects of macrophage-expressed urokinase and accelerates atherosclerosis in apoE-knockout mice. Proc Natl Acad Sci USA. 2008; 105:17109-17114.
25. Dellas C, Schremmer C, Hasenfuss G, Konstantinides SV, Schafer K. Lack of urokinase plasminogen activator promotes progression and instability of atherosclerotic lesions in apolipoprotein E-knockout mice. Thromb Haemost. 2007;98:220-227.
26. Rosenfeld ME, Polinsky P, Virmani R, Kauser K, Rubanyi G, Schwartz SM. Advanced atherosclerotic lesions in the innominate artery of the ApoE knockout mouse. Arterioscler Thromb Vasc Biol. 2000;20: 2587-2592.
27. Falkenberg M, Tom C, DeYoung MB, Wen S, Linnemann R, Dichek DA. Increased expression of urokinase during atherosclerotic lesion development causes arterial constriction and lumen loss, and accelerates lesion growth. Proc Natl Acad Sci USA. 2002;99:10665-10670.
28. Dichek DA, Lee SW, Nguyen NH. Characterization of recombinant plasminogen activator production by primate endothelial cells transduced with retroviral vectors. Blood. 1994;84:504-516.
29. Stempien-Otero A, Plawman A, Meznarich J, Dyamenahalli T, Otsuka G, Dichek DA. Mechanisms of cardiac fibrosis induced by urokinase plasminogen activator. J Biol Chem. 2006;281:15345-15351.
30. Stahle-Backdahl M, Parks WC. 92-kd Gelatinase is actively expressed by eosinophils and stored by neutrophils in squamous cell carcinoma. Am J Pathol. 1993;142:995-1000.
31. Gong Y, Hart E, Shchurin A, Hoover-Plow J. Inflammatory macrophage migration requires MMP-9 activation by plasminogen in mice. J Clin Invest. 2008;118:3012-3024.
32. Krishnan R, Kremen M, Hu JH, Emery I, Farris SD, Slezicki KI, Chu T, Du L, Dichek HL, Dichek DA. Level of macrophage uPA expression is an important determinant of atherosclerotic lesion growth in Apoe\/\mice. Arterioscler Thromb Vasc Biol. 2009;29:1737-1744.
33. Schapira K, Heeneman S, Daemen MJ. Animal models to study plaque vulnerability. Curr Pharm Des. 2007;13:1013-1020.
34. Johnson JL, Jackson CL. Atherosclerotic plaque rupture in the apolipoprotein E knockout mouse. Atherosclerosis. 2001;154:399-406.
35. Johansson F, Kramer F, Barnhart S, Kanter JE, Vaisar T, Merrill RD, Geng L, Oka K, Chan L, Chait A, Heinecke JW, Bornfeldt KE. Type 1 diabetes promotes disruption of advanced atherosclerotic lesions in LDL receptor-deficient mice. Proc Natl Acad Sci USA. 2008;105:2082-2087.
36. Clarke MC, Figg N, Maguire JJ, Davenport AP, Goddard M, Littlewood TD, Bennett MR. Apoptosis of vascular smooth muscle cells induces features of plaque vulnerability in atherosclerosis. Nat Med. 2006;12: 1075-1080.
37. Rader DJ, Daugherty A. Translating molecular discoveries into new therapies for atherosclerosis. Nature. 2008;451:904-913.
38. Kienast J, Padro T, Steins M, Li CX, Schmid KW, Hammel D, Scheld HH, van de Loo JC. Relation of urokinase-type plasminogen activator expression to presence and severity of atherosclerotic lesions in human coronary arteries. Thromb Haemost. 1998;79:579-586.
39. Leclercq A, Houard X, Loyau S, Philippe M, Sebbag U, Meilhac O, Michel JB. Topology of protease activities reflects atherothrombotic plaque complexity. Atherosclerosis. 2007;191:1-10.
40. Sayed S, Cockerill GW, Torsney E, Poston R, Thompson MM, Loftus IM. Elevated tissue expression of thrombomodulatory factors correlates with acute symptomatic carotid plaque phenotype. Eur J Vasc Endovasc Surg. 2009;38:20-25.
41. Svensson PA, Olson FJ, Hagg DA, Ryndel M, Wiklund O, Karlstrom L, Hulthe J, Carlsson LM, Fagerberg B. Urokinase-type plasminogen activator receptor is associated with macrophages and plaque rupture in symptomatic carotid atherosclerosis. Int J Mol Med. 2008;22:459-464.
42. Eggesbo JB, Hjermann I, Ovstebo R, Joo GB, Kierulf P. LPS induced procoagulant activity and plasminogen activator activity in mononuclear cells from persons with high or low levels of HDL lipoprotein. Thromb Res. 1995;77:441-452.
43. Gyongyosi M, Glogar D, Weidinger F, Domanovits H, Laggner A, Wojta J, Zorn G, Iordanova N, Huber K. Association between plasmin activation system and intravascular ultrasound signs of plaque instability in patients with unstable angina and non-ST-segment elevation myocardial infarction. Am Heart J. 2004;147:158-164.
44. Folsom AR, Aleksic N, Park E, Salomaa V, Juneja H, Wu KK. Prospective study of fibrinolytic factors and incident coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) Study. Arterioscler Thromb Vasc Biol. 2001;21:611-617. (Pubitemid 32323396)
45. Cushman M, Lemaitre RN, Kuller LH, Psaty BM, Macy EM, Sharrett AR, Tracy RP. Fibrinolytic activation markers predict myocardial infarction in the elderly: the Cardiovascular Health Study. Arterioscler Thromb Vasc Biol. 1999;19:493-498.
46. Morange PE, Bickel C, Nicaud V, Schnabel R, Rupprecht HJ, Peetz D, Lackner KJ, Cambien F, Blankenberg S, Tiret L. Haemostatic factors and the risk of cardiovascular death in patients with coronary artery disease: the AtheroGene study. Arterioscler Thromb Vasc Biol. 2006;26: 2793-2799.
47. Slager CJ, Wentzel JJ, Gijsen FJ, Thury A, van der Wal AC, Schaar JA, Serruys PW. The role of shear stress in the destabilization of vulnerable plaques and related therapeutic implications. Nat Clin Pract Cardiovasc Med. 2005;2:456-464.
48. Newby AC, George SJ, Ismail Y, Johnson JL, Sala-Newby GB, Thomas AC. Vulnerable atherosclerotic plaque metalloproteinases and foam cell phenotypes. Thromb Haemost. 2009;101:1006-1011.